SCHEMBL14750660

SCHEMBL14750660

CCOC(=O)COc1c(C)ccc(O)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.48
▸ GAA P10253 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CASP3 P42574 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ CASP9 P55211 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ NLRP3 Q96P20 2/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ATM Q13315 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7391291 0.87 SCN5A (0.50) ESR1GAANPSR1CASP3CASP7
SCHEMBL14754055 0.84 ESR1 (0.46) ESR1GAANPSR1CASP3CASP7
SCHEMBL14750655 0.81 CD69 (0.46) SMN1; SMN2L3MBTL1
SCHEMBL2058956 0.80 NLRP3 (0.57) GAANPSR1NLRP3ALDH1A1KDM4E
SCHEMBL14252839 0.78 CA12 (0.55) ESR1GAANPSR1CASP3CASP7
SCHEMBL7962735 0.76 CASP3 (0.49) ESR1GAANPSR1CASP3CASP7
SCHEMBL14252837 0.75 USP2 (0.55) ESR1GAANPSR1CASP3CASP7
SCHEMBL16784834 0.75 ALDH1A1 (0.52) ESR1GAANPSR1HPGDALDH1A1
SCHEMBL2037512 0.74 HPGD (0.59) ESR1GAANPSR1HPGDALDH1A1
SCHEMBL22542335 0.74 HPGD (0.63) ESR1GAANPSR1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ESR1 3870/4885GAA 202/4885NPSR1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback